News - Page 84 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

Post published:October 6, 2022
Post category:Press Release

Read more about the article MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

MindMed to Participate in the Cantor Fitzgerald Neurology & Psychiatry Conference

Post published:October 6, 2022
Post category:Press Release

Read more about the article Numinus Develops Mushroom Tea for Use in Psychedelic Research

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Post published:October 6, 2022
Post category:Press Release

Read more about the article Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Mindset Pharma Selects Lead Clinical Candidates From “Family 2” of its Next Generation Psychedelic Drug Portfolio

Post published:October 6, 2022
Post category:Press Release

Read more about the article PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

Post published:October 5, 2022
Post category:Press Release

Read more about the article atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

Post published:October 5, 2022
Post category:Press Release

Read more about the article MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA

Post published:October 5, 2022
Post category:Press Release

Read more about the article KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Post published:October 4, 2022
Post category:Press Release

Read more about the article Interview | George Tziras, Small Pharma

Interview | George Tziras, Small Pharma

Post published:October 4, 2022
Post category:Interview

Read more about the article Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Post published:October 4, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.